Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 30, 2024
Distillery Therapeutics

Inhibiting PRMT5 for heart failure

BioCentury | Dec 1, 2023
Discovery & Translation

CorrectSequence’s hemoglobin base editor; plus Denali’s LXR agonist and more

BioCentury’s roundup of translational innovations
BioCentury | May 3, 2023
Distillery Therapeutics

SMAD3 inhibitor for fibrosis

BioCentury | Aug 14, 2020
Translation in Brief

Hesperos applies organ-on-a-chip tech to ALS, Sinopharm details interim COVID-19 vaccine readout and more

BioCentury’s roundup of translational news
BioCentury | Aug 10, 2018
Targets & Mechanisms

Getting to function

How a new sarcopenia target could directly address muscle function deficits
BioCentury | Mar 21, 2017
Distillery Therapeutics

Cancer

BioCentury | Feb 28, 2017
Distillery Techniques

Biomarkers

BioCentury | Apr 3, 2014
Targets & Mechanisms

Narrowing down graft stenosis

BioCentury | Jun 3, 2013
Product Development

The DMD landscape

Looking beyond the first Duchenne muscular dystrophy therapies
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Hepatic disease

Items per page:
1 - 10 of 13